| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC2104 |
| Trial ID | NCT03939026 |
| Disease | Follicular Lymphoma | Relapsed/Refractory Diffuse Large B-Cell Lymphoma |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | ALLO-501 |
| Co-treatment | ALLO-647 |
| Phase | Phase1 |
| Recruitment status | Active, Not Recruiting |
| Title | Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma |
| Year | 2019 |
| Country | United States |
| Company sponsor | Allogene Therapeutics |
| Other ID(s) | ALLO-501-201 |
| Cohort 1 | |||||||||||
|
|||||||||||